CompletedPhase 2NCT04283669
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Studying Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Alabama at Birmingham
- Principal Investigator
- Girish Dhall, MDUniversity of Alabama at Birmingham
- Intervention
- Crizotinib(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2020 – 2025
Study locations (15)
- The University of Alabama at Birmingham (Site 700), Birmingham, Alabama, United States
- Univ of California @ Los Angeles (Site 325), Los Angeles, California, United States
- Children's National Medical Center (Site 775), Washington D.C., District of Columbia, United States
- Children's HealthCare of Atlanta (Site 950), Atlanta, Georgia, United States
- Lurie Childrens Hospital of Chicago (Site 350), Chicago, Illinois, United States
- University of Chicago (Site 850), Chicago, Illinois, United States
- Indiana University (Site 400), Indianapolis, Indiana, United States
- Johns Hopkins University (Site 250), Baltimore, Maryland, United States
- Children's Hospital Boston (Site 725), Boston, Massachusetts, United States
- Washington University - St. Louis (Site 900), St Louis, Missouri, United States
- New York University Medical Center (Site 200), New York, New York, United States
- Memorial Sloan Kettering Cancer Center (Site 210), New York, New York, United States
- Cincinnati Children's Hospital Medical Center (Site 800), Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia (Site 750), Philadelphia, Pennsylvania, United States
- Childrens Medical Center - Univ. of Texas SW (Site 917), Dallas, Texas, United States
Collaborators
Memorial Sloan Kettering Cancer Center · Children's Hospital of Philadelphia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04283669 on ClinicalTrials.govOther trials for Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07407803Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform NeurofibromasChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGNANCT07233408Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health LiteracyMassachusetts General Hospital
- RECRUITINGPHASE2NCT06188741Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1University of Alabama at Birmingham
- RECRUITINGNANCT06360406Real-World Treatment Study of Koselugo (Selumetinib)AstraZeneca
- RECRUITINGPHASE1, PHASE2NCT06159166Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).Johns Hopkins University
- RECRUITINGPHASE1NCT06104488A Study of Avutometinib for People With Solid Tumor CancersMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT05521048Doxycycline in Cutaneous Schwannoma (NF2)Massachusetts Eye and Ear Infirmary
- ACTIVE NOT RECRUITINGNANCT03873610Resiliency Training in Adolescents With NF1 and NF2Massachusetts General Hospital
See all trials for Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion →